FibroGen Earnings Call Highlights Clinical Momentum, Runway

FibroGen ((KYNB)) has held its Q1 earnings call. Read on for the main highlights of the call.

FibroGen’s latest earnings call struck a cautiously optimistic tone as management highlighted strengthening clinical data, tighter cost control, and an extended cash runway into 2028. While executives acknowledged ongoing net losses, safety questions, and heavy reliance on upcoming trial readouts, they argued that emerging efficacy signals and regulatory traction are beginning to rebalance the risk‑reward profile.

Revenue Growth and Improving Financial Discipline

FibroGen posted Q1 2026 revenue of $3.7 million, up about 37% from $2.7 million a year earlier, underscoring early but tangible top‑line momentum. Management paired this with a narrower net loss of $15.1 million and essentially flat operating costs, signaling a tighter focus on capital allocation.

R&D and SG&A Cuts Support a Leaner Model

The company kept total operating expenses at $17.6 million versus $17.7 million last year, while reshaping the spend mix. Research and development dropped roughly 17% to $7.6 million and SG&A fell about 27% to $5.9 million, indicating disciplined investment behind the most promising clinical assets.

Cash Runway into 2028 Reduces Near-Term Financing Pressure

With $100.3 million in cash, equivalents, investments and receivables at March 31, management reiterated that the balance sheet can fund U.S. pipeline activities into 2028. For equity investors, this multi‑year runway meaningfully lowers the risk of imminent dilution while the company works toward key value‑defining data.

FG-3246 Monotherapy Shows Meaningful Efficacy in mCRPC

In heavily pretreated metastatic castration‑resistant prostate cancer, Phase I monotherapy data for FG‑3246 showed a median radiographic progression‑free survival of 8.7 months. The program also delivered PSA reductions of more than 50% in 36% of patients and a 20% overall response rate with a 7.5‑month median duration of response.

Dose-Response Signal Centers on 2.7 mg/kg Cohort

All observed objective responses in the FG‑3246 monotherapy study occurred at the 2.7 mg/kg dose level, suggesting a meaningful dose‑response relationship. This has guided dose selection for the ongoing Phase II trial, where the company aims to optimize exposure while managing safety risks such as neutropenia.

Combination with Enzalutamide Adds to the Efficacy Story

An investigator‑initiated trial combining FG‑3246 with enzalutamide in 44 patients reported a median rPFS of 7.0 months in an all‑comer cohort. Notably, patients who had progressed on only one prior AR pathway inhibitor achieved a median rPFS of 10.1 months and a PSA50 response rate of 40%, reinforcing the asset’s potential in earlier‑line settings.

FG-3180 PET Imaging Emerging as a Companion Diagnostic Candidate

Data from an investigator‑sponsored trial showed that higher FG‑3180 tumor uptake on PET imaging trended with greater PSA50 responses to FG‑3246. This is the first demonstrated association between CD46 expression and response, supporting FG‑3180 as a potential companion diagnostic to enrich future Phase III populations.

Biomarker Signal Promising but Not Yet Statistically Conclusive

Despite the encouraging trend, the nominal p‑value for the FG‑3180 uptake and PSA50 association narrowly missed statistical significance in the study. Management framed the biomarker as “suggestive but unproven” and plans to use the ongoing Phase II trial to better define how CD46‑high selection could sharpen efficacy in a pivotal setting.

Neutropenia Risk and a Validated Mitigation Strategy

Early FG‑3246 monotherapy work showed notable grade 3 or higher neutropenia, which led to dose interruptions and down‑titrations, underscoring a key safety concern for the ADC program. In the investigator‑sponsored study, primary G‑CSF prophylaxis substantially reduced severe neutropenia, and this strategy has now been fully integrated into the Phase II trial design.

Roxadustat Gains Ground in Lower-Risk MDS

Roxadustat secured orphan drug status for lower‑risk myelodysplastic syndromes and showed compelling post‑hoc subgroup data from the MATTERHORN trial. Among patients with high transfusion burden, 36% on roxadustat achieved at least eight weeks of transfusion independence versus 7% on placebo, supporting a more targeted registrational strategy.

Subgroup Data Support a Focused Phase III Design

The company plans to concentrate roxadustat development on roughly 49,000 U.S. lower‑risk MDS patients who are refractory or ineligible to ESAs. Leveraging the high‑burden subgroup signal, the upcoming Phase III will use eight‑week transfusion independence as the primary endpoint, with 12‑ and 16‑week measures as key secondary outcomes.

Persistent Net Losses and Modest Revenue Base Temper Upside

Despite improved expense control and revenue growth, FibroGen still reported a Q1 net loss of $15.1 million and a small $3.7 million revenue base. Until a product reaches commercialization or meaningful milestone payments are secured, the equity story remains that of a clinical‑stage company reliant on successful execution rather than cash flows.

Unclear Enrollment Pace Adds Execution Risk

Management disclosed that 21 sites have been activated for the FG‑3246 Phase II dose‑optimization study but did not share enrollment numbers. That omission leaves investors guessing whether recruitment is on track to support the planned Q4 2026 interim analysis, adding an element of timing risk to near‑term catalysts.

Strategic Uncertainty Around Roxadustat Commercial Path

The company is still weighing whether to advance roxadustat alone or secure a strategic partner for Phase III and eventual commercialization. This unresolved strategy could affect both the pace of development and future economics, and investors will be watching closely for clarity on deal appetite and partnering terms.

Heavy Dependence on Upcoming Clinical Milestones

FibroGen’s valuation is increasingly tied to binary outcomes from the FG‑3246 Phase II trial and the roxadustat Phase III program. Management acknowledged that regulatory and execution risks around these readouts remain substantial, but argued that the strengthening data package and FDA interactions justify pressing ahead toward potential pivotal trials.

Forward-Looking Guidance Points to 2026–2027 Catalysts

Management guided to a Q4 2026 interim analysis for the 75‑patient FG‑3246 monotherapy Phase II trial, aiming for a median rPFS benchmark of at least 10 months and detailed readouts on PSA50, ORR, safety and exposure‑response. Mature rPFS data are expected in 2027, while the roxadustat Phase III in lower‑risk MDS is slated to begin in the second half of 2026, all funded by a cash runway extending into 2028.

FibroGen’s call painted a picture of a more focused, better‑funded clinical company leaning hard into oncology and hematology opportunities. Investors are being asked to look past ongoing losses and safety questions in exchange for meaningful upside if FG‑3246 and roxadustat hit their ambitious late‑stage milestones over the next two years.